|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating activities: | |||||
| Net income | |||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||
| Depreciation and amortization | |||||
| Stock-based compensation | |||||
| Deferred taxes | |||||
| Fair value loss on Promissory Note | |||||
| Gain on deconsolidation of Bakkt | |||||
| (Gains)/losses on sale of investments | |||||
| Net losses from and impairment of unconsolidated investees | |||||
| (Gain)/Loss on investments | |||||
| Net (income)/losses from unconsolidated investees | |||||
| Other | |||||
| Changes in assets and liabilities: | |||||
| Customer accounts receivable | |||||
| Other current and non-current assets | |||||
| Section 31 fees payable | |||||
| Deferred revenue | |||||
| Other current and non-current liabilities | |||||
| Total adjustments | |||||
| Net cash provided by operating activities | |||||
| Investing activities: | |||||
| Capital expenditures | |||||
| Capitalized software development costs | |||||
| Cash paid for acquisitions, net of cash acquired | |||||
| Proceeds from sale of Promissory Note | |||||
| Purchases of invested margin deposits | |||||
| Proceeds from invested margin deposits | |||||
| Purchases of equity and equity method investments | |||||
| Proceeds from the sale of equity investments | |||||
| Purchases of restricted investments | |||||
| Proceeds from restricted investments | |||||
| Proceeds from/(purchases of) other investments, net | |||||
| Other investing activities | |||||
| Net cash used in investing activities | |||||
| Financing activities: | |||||
| Proceeds from debt issuances | |||||
| Repayments of debt | |||||
| Proceeds from/(redemption of) commercial paper, net | |||||
| Repurchases of common stock | |||||
| Dividends paid to stockholders | |||||
| Change in cash and cash equivalent margin deposits and guaranty funds liability | |||||
| Payments relating to treasury shares received for restricted stock tax payments and stock option exercises | |||||
| Other financing activities | |||||
| Net cash provided by/(used in) financing activities | |||||
| Effect of exchange rate changes on cash, cash equivalents, restricted cash and cash equivalents, and cash and cash equivalent margin deposits and guaranty funds | |||||
| Net increase/(decrease) in cash, cash equivalents, restricted cash and cash equivalents, and cash and cash equivalent margin deposits and guaranty funds | |||||
| Cash, cash equivalents, restricted cash and cash equivalents, and cash and cash equivalent margin deposits and guaranty funds at beginning of period | |||||
| Cash, cash equivalents, restricted cash and cash equivalents, and cash and cash equivalent margin deposits and guaranty funds at end of period | |||||
| Supplemental cash flow disclosure: | |||||
| Cash paid for interest | |||||
| Cash paid for income taxes | |||||
| Cash paid for amounts included in the measurement of operating lease liability | |||||
| Lease liabilities arising from obtaining right-of-use assets | |||||
| Reconciliation of the components of cash, cash equivalents, restricted cash and cash equivalents, and cash and cash equivalent margin deposits and guaranty funds to the consolidated balance sheets: | |||||
| Cash and cash equivalents | |||||
| Short-term restricted cash and cash equivalents | |||||
| Long-term restricted cash and cash equivalents | |||||
| Cash and cash equivalent margin deposits and guaranty funds | |||||
Loading...